A Phase 3 interventional study of Cefotaxime and Gemifloxacin in Spontaneous Bacterial Peritonitis, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Tanta University · Phase 3, Interventional, and Treatment
oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis
Comparative Study between the Efficacy of oral Gemifloxacin and intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis
167 studies on the registry are indexed under Peritonitis; 23 are open to participants now.
This study's planned enrollment of 60 is below the median of 79 across 106 interventional studies indexed under Peritonitis.
Browse Peritonitis studies →Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cefotaxime intravenous
Drug: Cefotaxime
Oral Gemifloxacin
Drug: Gemifloxacin
Cefotaxime IV
Also known as: cefotax, claforan
Gemifloxacin oral
Also known as: gemiflox
Number of patients with resolution of infection
the total number of patients with resolution of infection
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cefotaxime